Harvey Holmes, Clare Morris and Neil Berry Division of Retrovirology

Slides:



Advertisements
Similar presentations
Preparation, characterization and establishment of a WHO International Biological Reference Preparation Dr Sjoerd Rijpkema Division of Bacteriology NIBSC.
Advertisements

Marta José, Instituto Grifols S.A., Barcelona, SPAIN
Replacement of the 1 st Parvovirus B19 DNA International Standard SoGAT XXI, Brussels, 28th-29th May 2009 Sally Baylis.
Development of a Panel for Dengue Virus Maria Rios, PhD CBER/FDA Blood Products Advisory Committee Meeting December 14, 2010.
NIBSC Multiplex Proficiency Panel - A multicentre study
National Institute for Biological Standards and Control Assuring the quality of biological medicines Proposal for a Hepatitis A genotype panel Rob Anderson.
Development of an HIV-2 RNA International Standard Harvey Holmes, Clare Morris, Neil Berry, Alan Heath and Collaborative Study Group.
Yi-Chen Yang, Drug Biology Division Bureau of Food and Drug Analysis Department of Health, Taiwan Collaborative study for establishment of the first national.
Paris, May 2004SoGAT XVII SoGAT and the Development of Standards Harvey Holmes Division of Retrovirology NIBSC, UK.
Karen Cristiano Biologicals Unit, CRIVIB Calibration against the WHO Standards of National Reference Preparations for detection of blood viruses by NAT:
Linearity Panels HIV RNA, HCV RNA, HBV DNA, and CMV DNA
XVIII SoGAT Washington 24 May 2005 SoGAT and HIV NAT Standards - 2 nd International Standard for HIV-1 RNA Harvey Holmes*, Clare Davis* and Alan Heath**
PROFICIENCY TESTING OF IN-HOUSE NAT ASSAYS USED FOR BLOOD SCREENING XXI SoGAT International Working Group Meeting on the Standardization of NAT for the.
BioLife Plasma Services Experience with HBV NAT Testing
1 HBV Genotype Panel Michael Chudy Section of Molecular Virolgy Division of Virology SoGAT XXI Meeting Brussels, May 2009.
HIV, HCV, and HBV NAT Controls Formulation, Stability and Performance Mark Manak BBI Diagnostics, Inc. A Division of SeraCare Life Sciences, Inc. SoGAT.
Update on CBER HIV NAT panels and International panels Indira Hewlett, Ph.D Chief, Lab. of Molecular Virology DETTD/OBRR/FDA May 28, 2009 XXI SoGAT meeting.
FDA’s Current Considerations of Parvovirus B19 Nucleic Acid Testing (NAT) Mei-ying W. Yu, PhD Division of Hematology CBER/FDA Extraordinary SoGAT Meeting.
Hepatitis E Virus – Progress in Standardization of NAT-Based Assays Blood Products Advisory Committee Rockville, 20 th September 2012 Sally.
ENIVD 06/06 02:19 First international proficiency study on West Nile virus molecular detection. Matthias Niedrig, Sonja Linke Christian Drosten Hervé Zeller.
Update on the Replacement of the HCV RNA International Standard Sally Baylis & Alan Heath, NIBSC SoGAT XX, Warsaw June 2007.
Evaluation of Viral Clearance Studies
CE MARKING OF IVDDs - the NIBSC perspective Morag Ferguson Division of Virology.
Standardization – CBER update June 12, 2007 XX SoGAT Indira Hewlett, Ph.D. Chief, Lab. of Molecular Virology DETTD/CBER/FDA.
Establishment of the 1st WHO International Standard for Detection of Antibodies to Hepatitis B Virus Core Antigen (anti-HBc) SoGAT XXI 29 May 2009 Dr.
Persistent human erythrovirus infection in blood donors National Blood Service, UK Div. Transfusion Medicine, University of Cambridge, UK Public Health.
HIV variants and US licensed assays Indira Hewlett, Ph.D Chief, Lab. of Molecular Virology CBER/FDA XIX SOGAT, 2006.
Parvovirus B19 Genotype 2 Plasma, Sourced from the US Dr Sally A. Baylis, Division of Virology NIBSC.
Stability of HCV, HIV-1 and HBV nucleic acids in plasma samples stored at different temperatures Marta José, Rodrigo Gajardo and Juan I. Jorquera Instituto.
Yi-Chen Yang, Yu-Hsuan Chen, Show-Lan Chiu, Hwei-Fang Cheng Drug Biology Division, Bureau of Food and Drug Analysis Department of Health, Taiwan, ROC National.
An Update on FDA/OBRR XMRV activities BPAC meeting, July 26, 2010 Indira Hewlett, Ph. D Chief, Laboratory of Molecular Virology DETTD/CBER/FDA.
SoGAT XVII/Paris, 2004 Proficiency Testing of In-House Developed HIV-1 NAT for Blood Screening Michael Chudy, Paul-Ehrlich-Institut Division of Virology,
National Institute for Biological Standards and Control Assuring the quality of biological medicines Human Cytomegalovirus (HCMV) Proposed 1 st International.
Development of Standard Reagents for WNV NAT M. Rios, A. Grinev, K. Sirnivasan, O. Wood, S. Daniel, I. Hewlett CBER/FDA.
History of ILC Involvement in NAT Standardization 1998: Inter-Organization Discussion for the Establishment of Standard Reference Material for Nucleic.
Blood Products & related Biologicals: SoGAT, 28 May 09 1 |1 | Dr Ana Padilla, Blood Products & related Biologicals Essential Medicines and Pharmaceutical.
Update on the P. falciparum Standard & Replacement of the HBV & HCV International Standards Sally Baylis, NIBSC SoGAT XIX.
NUCLEIC ACID AMPLIFICATION TECHNOLOGY HCV-RNA / HBV-DNA / HIV-RNA testing blood and blood components for transfusion Italian External Quality Assessment.
International Scientific Workshop on the Standardization of Genome Amplification Techniques for the Safety Testing of Blood, Tissues and Organs With Regard.
Preparation of HBV DNA reference standards and the experience of HBV NAT in Taiwan Dr. Hwei-Fang Cheng Department of Health, Taiwan.
NIBSC 2 March 2007 The European Directorate for the Quality of Medicines and Health Care issues of concern regarding the detection of B19 in blood:plasma.
Evaluation of Viral Clearance Studies Mahmood Farshid, Ph.D. Div. Of Hematology OBRR/ CBER/FDA.
An Overall View of Standardization May 26, 2004 Indira Hewlett, Ph.D. CBER/FDA.
Phar. Nhat Mang/ Roche Vietnam
CBER Update on status of West Nile virus test, lot release and validation panel development Indira Hewlett, Ph.D CBER/FDA Blood Products Advisory Committee.
Informational Presentation: WHO Biological Standards Summary of January 29-30, 2007 WHO Meeting with WHO Collaborating Centres for Biological Standards.
SOGAT Presence (absence) of genotype 2 and 3 Erythrovirus DNA in manufacturing plasma Theo Cuypers, Marco Koppelman, Margret Sjerps, Henk Reesink.
HBV DNA Quantification: Results from the UK NEQAS Proficiency Panel
Basics of HIV Virus Vijay Kandula, MD MPH AAHIVS
Saeko Mizusawa, Yoshiaki Okada
Chief, Laboratory of Molecular Virology, CBER, FDA
GRIFOLS PLASMA: genotype 2 vB19 sample
Testing for Parvovirus B19 - Broadening the Assay to Cover Variants
Results of Recent EQA Panels for Blood Borne Viruses
Preparation of plasmids containing HBV-full genome of genotype A to H and trial of HBV inactivation method Yoshiaki Okada Kiyoko Umemori Kazunari.
Update on CBER HIV-1 Subtype panel
Evaluation data on the new Roche cobas s 201 system with the cobas TaqScreen MPX test Lutz Pichl, Volkmar Schottstedt German Red Cross Blood Transfusion.
Evaluation of Candidate Standard XX (97/650)
K.H. Buchheit, A. Daas, C.M. Nübling, J.M. Spieser 3 July 2003
Feasibility of Synthetic Materials as Primary Standards
Italian EQA study for HCV RNA, HIV RNA and HBV DNA G. M. Bisso, K
1st International Standard for HIV-1 RNA NIBSC Code 97/656
Distributions of parvovirus B19 genotype 1-3 in blood donations
SoGAT Meeting, Berne, 14 June 2006 M. Nübling (PEI, Germany)
Comparison of a commercial and ‘in house’ assay for B19 DNA
Evaluation of the Abbott Investigational Use Only RealTime HIV-1 Assay and Comparison to the Roche Amplicor HIV-1 Monitor Test, Version 1.5  Michael T.
SoGAT meeting XXI May (2009), Brussels, Belgium
Preparation of QC and Training Panels
Rapid Detection of HIV-1 subtype C Integrase resistance mutations by the Use of High-Resolution Melting Analysis Tendai Washaya BSc, Msc. Pre-PhD Student.
ANALYTICAL CONTROL SYSTEM AS A MEASURE TO ENSURE INFECTIOUS SAFETY OF HUMAN PLASMA FOR FRACTIONATION A.L. Poptsov FSBI “ROSPLASMA” RMSPC of FMBA of RUSSIA.
Presentation transcript:

Harvey Holmes, Clare Morris and Neil Berry Division of Retrovirology Plans for International Standard for HIV-2 RNA and 2nd Second International Reference Panel for HIV-1 RNA Genotypes Harvey Holmes, Clare Morris and Neil Berry Division of Retrovirology NIBSC, UK (In collaboration with Indira Hewlett, CBER/FDA)

Current HIV Reference Reagents Available from NIBSC 2nd International Standard for HIV-1 RNA. (code 97/650) Unitage 5.56 IU Log 10/ml International Reference Panel for HIV-1 RNA Genotypes (code 01/466) established in 2003 No unitage assigned Working reagents for NAT Working Reagent 1 – medium copy number (3.56 log10 IU/ml) Working Reagent 2 – high copy number (4.56 log10 IU/ml) Working Reagent 3 – low copy number (2.56 log10 IU/ml) Working Reagents and Proficiency Samples can also be made at NIBSC under contract to a pre-defined concentration and using various HIV-1 strains and genotypes

International Standard for HIV-2 RNA Rationale Global HIV pandemic due to HIV-1 Most NAT assays aimed at HIV-1 detection and quantification HIV-2 mainly found in West Africa and European countries with close links – eg Portugal, France, Belgium. Assays capable of detecting HIV-2 RNA or both HIV-1/HIV-2 are either available (eg Roche Cobas Taqscreen MPX) or in development International Standard for the HIV-2 RNA component would be valuable once assays in wider use Anticipated need/usage Currently limited demand Once commercial assays that can detect HIV-2 more available, demand may be greater WHO Status New project – endorsed by ECBS in October 2006 Discussed at meeting of WHO Collaborating Centres in Jan 07

Key Scientific issues Few commercial assays available that can detect/quantitate HIV-2 RNA At NIBSC, in house real-time PCR assay based on LTR sequence used for HIV-2 quantification Source/Type of Material To be based on HIV-2 grown in culture and diluted in negative plasma Currently assessing representatives of HIV-2 subtype A and subtype B Suitable strain(s) to be selected and stock laid down Virus stock to be characterised and sequence confirmed Heat inactivation to be evaluated Batch to be freeze-dried International collaborative study to be organised

Amplification of HIV2 ROD log dilution series

Standard Curve of HIV2 ROD standards

500 panels prepared and frozen at -80C 1st International Reference Panel for HIV-1 RNA Genotypes (code 01/466) Established by ECBS in 2003 500 panels prepared and frozen at -80C Contains representatives of HIV-1: Subtypes A, B, C, D, AE, F, G, AGH Group N and O ~120 panels remain Stability at -80C very good over 5 years Proposal for 2nd IRP

Second Genotype Panel for HIV-1 RNA Rationale Many inter-subtype recombinant forms now circulating (CRF01 – CRF32) Increasingly being encountered – important pandemic strains Less common subtypes may be difficult to detect Proposal to prepare extended panel containing: Subtypes G, H, J and K, group N and O Range of CRFs Will give kit manufacturers and others access to rare and challenging strains of HIV to enable them to assess their ability to detect these viruses Anticipated need/usage Discussed at SoGAT working group meeting Limited need Provides a source of well characterised diverse CRFs and isolates WHO Status Project endorsed by ECBS October 2006 Discussed at meeting of WHO Collaborating Centres in Jan 07

Second Genotype Panel for HIV-1 RNA Source/Type of Material Only relatively small number of characterised viruses belonging to uncommon subtypes or CRFs available as infectious virus many only available as cloned DNA Will source viruses from CFAR/NIBSC, CBER and NIH ARRRP and from scientists who have described them in the literature Viruses to be grown in PBMC culture and seed stocks stored down Viruses will be characterised including sequence confirmation Viruses will be spiked into HIV-negative plasma Heat inactivation and freeze-drying to be evaluated International collaborative study to be organised

HIV field isolates, reference strains and CRFs currently available Subtype G Subtype H Subtype J Subtype K Group N (to be sourced) Group O HIV-2 Subtype A HIV-2 subtype B CRF01_AE CRF02_AG CRF04_AGHKU (plasma only) CRF07_BC CRF11_A01GJ CRF13_A01GJU CRF14_BG